Lenalidomide Monotherapy in R/R DLBCL
Public ClinicalTrials.gov record NCT04150328. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Official title
An Observational Retrospective Cohort Study of Lenalidomide Monotherapy in Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL) to Generate a Historical Control for Clinical Trial MOR208C203 (RE-MIND)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This observational study is designed to characterise the effectiveness of lenalidomide monotherapy in the treatment of R/R DLBCL and to compare the results with the efficacy outcomes of a tafasitamab-lenalidomide combination therapy in the clinical trial MOR208C203 (L-MIND)
Study identification
- NCT ID
- NCT04150328
- Recruitment status
- Completed
- Study type
- Observational
- Phase
- Not listed
- Enrollment
- 490 participants
Conditions and interventions
Conditions
Interventions
Not listed
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 12, 2019 (Actual)
- Primary completion
- Aug 25, 2019 (Actual)
- Completion
- Aug 25, 2020 (Actual)
- Last update posted
- Aug 24, 2022
2019 – 2020
United States locations
- U.S. sites
- 8
- U.S. states
- 5
- U.S. cities
- 8
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| MorphoSys Research Site | Rochester | Minnesota | 55905 | — |
| MorphoSys Research Site | St Louis | Missouri | 63110 | — |
| MorphoSys Research Site | Manhasset | New York | 11030 | — |
| MorphoSys Research Site | New York | New York | 10013 | — |
| MorphoSys Research Site | Rochester | New York | 14642 | — |
| MorphoSys Research Site | Dublin | Ohio | 43017 | — |
| MorphoSys Research Site | Charleston | South Carolina | 29425 | — |
| MorphoSys Research Site | Greenville | South Carolina | 29615 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 49 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04150328, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 24, 2022 · Synced Nov 5, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT04150328 live on ClinicalTrials.gov.